In This Article:
OKYO Pharma (OKYO) has received $1.4M in non-dilutive funding. The company said, “This significant financial funding strengthens the Company’s ability to advance its innovative pipeline without diluting shareholder value. The funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on fueling progress with OKYO’s lead program, OK-101 focused on treating NCP, a major unmet medical need.”
Invest with Confidence:
-
Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
-
Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OKYO: